Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2000, p. 2179-2181, Vol. 44, No. 8
Department of Internal Medicine,
Inselspital,1 Department of Internal
Medicine, Zieglerspital,2 and
Institute of Medical Microbiology, University of
Bern,3 Bern, Switzerland
Received 27 October 1999/Returned for modification 6 March
2000/Accepted 8 May 2000
The bactericidal activities of monotherapy with trovafloxacin
(
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Synergy between Trovafloxacin and Ceftriaxone
against Penicillin-Resistant Pneumococci in the Rabbit Meningitis
Model and In Vitro
0.37 ± 0.15
log10 CFU/ml · h),
vancomycin (
0.32 ± 0.12
log10 CFU/ml · h), and ceftriaxone (
0.36 ± 0.19
log10
CFU/ml · h) for the treatment of experimental meningitis in
rabbits due to a clinical penicillin-resistant pneumococcal strain
(MIC, 4 mg/liter) were similar. The combination of ceftriaxone with
trovafloxacin considerably improved the killing rates (
0.67 ± 0.16
log10 CFU/ml · h) and was slightly superior
to ceftriaxone with vancomycin (killing rate,
0.53 ± 0.22
log10 CFU/ml · h), the regimen most commonly used
in clinical practice. In vitro, synergy was demonstrated between
ceftriaxone and trovafloxacin by the checkerboard method (fractional
inhibitory concentration index, 0.5) and by time-killing assays over
8 h.
*
Corresponding author. Mailing address: Department of
Internal Medicine, Inselspital, 3010 Bern, Switzerland. Phone:
41316322111. Fax: 41316323847. E-mail: pcottagn{at}insel.ch.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |